April 3, 2026
The Fourth Circuit Court of Appeals has issued a major whistleblower ruling in United States ex rel. Sheldon v. Allergan Sales LLC, reversing a district court dismissal and clarifying how scienter should be evaluated under the False Claims Act (FCA) when regulatory ambiguity exists. The decision is a significant development for FCA enforcement—particularly in cases involving complex pricing and rebate rules under the Medicaid Drug Rebate Program.
This article explains the decision, why it matters, and what whistleblowers and their attorneys should take away as they evaluate potential fraud involving government program pricing.
A former pharmaceutical employee filed a complaint under the qui tam provisions of the FCA. The whistleblower alleged that Allergan failed to properly calculate and report “Best Price” figures for certain drugs under the Medicaid Rebate Statute. According to the complaint, from 2005 to 2014, the company failed to aggregate rebates and discounts provided to different entities. This resulted in inflated Best Price reports and underpayment of rebates owed to Medicaid.
The district court dismissed the case, even in light of the Supreme Court’s then‑recent clarification of the FCA scienter standard in U.S. ex rel. Schutte v. SuperValu Inc.. In SuperValu, the Supreme Court held that the relator had not adequately alleged subjective scienter and that statutory ambiguity weighed against a finding of falsity.
On March 13, 2026, the Fourth Circuit reversed, holding that the complaint plausibly alleged subjective scienter under SuperValu. The court found the relator had sufficiently pled that Allergan knew that its claims were false.
The panel emphasized that statutory ambiguity does not negate scienter at the pleading stage, nor does it bar the relator from establishing falsity. The decision remanded the case for further proceedings, directing the district court to consider falsity in the first instance.
Defendants frequently argue that ambiguous statutes or regulations shield them from FCA liability because they could have adopted a “reasonable interpretation.” After SuperValu, this argument became significantly weaker—and the Fourth Circuit’s ruling reinforces that:
By holding that alleged knowledge of agency interpretation and internal compliance concerns can establish plausible scienter, the court has lowered the barrier for whistleblowers to survive dismissal.
The relator pointed to internal audit efforts and the company’s communications with CMS during the 2006–2007 rulemaking period as evidence of subjective awareness.
For whistleblowers, this reinforces the value of:
Such documents can play a decisive role in establishing scienter, particularly in complex pricing schemes.
The Fourth Circuit’s ruling aligns with a broader enforcement trend: increasing scrutiny of drug pricing, rebate miscalculations, and market access agreements.
The Medicaid Rebate Statute requires drug manufacturers to disclose the lowest price they offer in the commercial market. If rebates and discounts are improperly “unstacked,” Medicaid may pay artificially high prices—precisely the fraud the FCA is designed to uncover.
For potential whistleblowers in the pharmaceutical industry, the ruling underscores what we predicted: pricing manipulation remains a ripe area for FCA litigation.
This is particularly relevant to whistleblowers in:
Whistleblowers should take note: materials that were once considered “soft guidance,” such as informal CMS feedback or draft rulemaking documents, can support scienter allegations.
Insiders with access to internal audits or compliance reports may now find a more welcoming judicial environment for claims that rely on such evidence.
Given the Fourth Circuit’s reasoning, relators should maintain detailed documentation of:
The Fourth Circuit’s decision in United States ex rel. Sheldon v. Allergan Sales LLC represents a significant step forward for whistleblowers seeking to hold companies accountable for defrauding government healthcare programs. By reaffirming that statutory ambiguity does not immunize defendants and by emphasizing subjective knowledge over hypothetical interpretations, the court has strengthened the pathway for FCA cases—particularly those involving complex pricing structures.
For potential relators, especially in the pharmaceutical and healthcare sectors, Sheldon underscores the importance of coming forward with internal evidence of misconduct. For attorneys, it provides a clear, up‑to‑date articulation of how to plead scienter in the post‑SuperValu landscape.
Whistleblowers with knowledge of pricing, rebate, or reporting manipulation should contact us to evaluate their potential claims.